Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele A Faulkner

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
CNS Drugs|February 27, 2018
Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom DiseaseMichele A Faulkner
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|January 17, 2014
Perampanel: a new agent for adjunctive treatment of partial seizuresMichele A Faulkner
Expert Opinion on Drug Safety|June 26, 2014
Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's diseaseMichele A Faulkner
Clinicoeconomics and Outcomes Research : CEOR|September 22, 2011
Smoking cessation: an economic analysis and review of vareniclineMichele A Faulkner
Drug Design, Development and Therapy|October 19, 2017
Spotlight on perampanel in the management of seizures: design, development and an update on place in therapyMichele A Faulkner
Therapeutics and Clinical Risk Management|June 20, 2015
Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndromeMichele A Faulkner
Expert Opinion on Drug Safety|July 26, 2013
Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanelMichele A Faulkner, Rachel A Burke
Expert Opinion on Pharmacotherapy|February 28, 2002
The economic impact of chronic obstructive pulmonary diseaseMichele A Faulkner, Daniel E Hilleman
Therapeutics and Clinical Risk Management|September 24, 2011
Treatment options for refractory and difficult to treat seizures: focus on vigabatrinJustin A Tolman, Michele A Faulkner
Journal of Central Nervous System Disease|May 8, 2013
Review of the treatment of restless legs syndrome: focus on gabapentin enacarbilRachel A Burke, Michele A Faulkner
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
CNS Drugs|February 27, 2018
Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom DiseaseMichele A Faulkner
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|January 17, 2014
Perampanel: a new agent for adjunctive treatment of partial seizuresMichele A Faulkner
Expert Opinion on Drug Safety|June 26, 2014
Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's diseaseMichele A Faulkner
Clinicoeconomics and Outcomes Research : CEOR|September 22, 2011
Smoking cessation: an economic analysis and review of vareniclineMichele A Faulkner
Drug Design, Development and Therapy|October 19, 2017
Spotlight on perampanel in the management of seizures: design, development and an update on place in therapyMichele A Faulkner
Therapeutics and Clinical Risk Management|June 20, 2015
Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndromeMichele A Faulkner
Expert Opinion on Drug Safety|July 26, 2013
Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanelMichele A Faulkner, Rachel A Burke
Expert Opinion on Pharmacotherapy|February 28, 2002
The economic impact of chronic obstructive pulmonary diseaseMichele A Faulkner, Daniel E Hilleman
Therapeutics and Clinical Risk Management|September 24, 2011
Treatment options for refractory and difficult to treat seizures: focus on vigabatrinJustin A Tolman, Michele A Faulkner
Journal of Central Nervous System Disease|May 8, 2013
Review of the treatment of restless legs syndrome: focus on gabapentin enacarbilRachel A Burke, Michele A Faulkner
Pageof 3